ºÚÁÏÍø

Quantitative Electroencephalography Analysis (qEEG) of Neuro-Electro- Adaptive Therapy 12™ [NEAT12] Up-Regulates Cortical Potentials in an Alcoholic during Protracted Abstinence: Putative Anti-Craving Implications

¹ Department of Nutrigenomic Research, Bio-Clarity, LLC, San Diego, California USA

² Department of Psychiatry and Neurology, Boston University School of Medicine and Veterans Administration System, Boston, Massachusetts, USA

³ Department of Psychiatry, University of Florida, College of Medicine and McKnight Brain Institute, Gainesville, Florida, USA

⁴ Center for Genomics and Applied Gene Therapy, Institute of Integrative Omics and Applied Biotechnology (IIOAB),Nonakuri, Purba Medinipur, West Bengal, India

⁵ Department of Addiction Research & Therapy, Malibu Beach Recovery Center, Malibu Beach, California, USA

⁶ Dominion Diagnostics, LLC., North Kingstown, Rhode Island, USA

⁷ Path Foundation NY, New York, New York, USA

*Corresponding Author:

Kenneth Blum
Department of Psychiatry and McKnight Brain Institute
University of Florida
College of Medicine, Gainesville, Fl., USA
Tel: 619-890-2167
E-mail: drd2gene@gmail.com

Received date: January 09, 2014; Accepted date: February 07, 2014; Published date: February 20, 2014

Citation: Waite RL, Oscar-Berman M, Braverman ER, Barh D, Blum K (2014) Quantitative Electroencephalography Analysis (qEEG) of Neuro-Electro-Adaptive Therapy 12™ [NEAT12] Up-Regulates Cortical Potentials in an Alcoholic during Protracted Abstinence: Putative Anti-Craving Implications. J Addict Res Ther 5:171. doi:10.4172/2155-6105.1000171

Copyright: © 2014 Waite RL, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Addiction Research & Therapy

Abstract

Introduction: Cranial electrotherapy stimulation (CES) is a noninvasive therapy that has been used for decades in the United States to treat anxiety, depression, and insomnia in the general population. The effectiveness of CES has been questioned by many and its use is considered controversial. In this study we are presenting data on one alcoholic patient using a newly engineered device we call Neuro-Electro-Adaptive Therapy 12™ [NEAT12]. This hybrid device utilizes TENS current characteristics yielding CES effects. This device has been found to primarily target the excitation of the Cingulate Gyrus region of the brain.

Case presentation: This is a 42 year old male who has been abstinent from alcohol for approximately two months. The data presented herein represents the pre to post qEEG differences of an alcoholic in protracted abstinence. This subject was evaluated both before and after using the NEAT-12 device. The pre to post comparisons suggest that the cortical potentials especially at the Cingulate Gyrus are up regulated after using the device. The absolute power changes obtained shows a decrease of more than 2 SD as noted in the delta wave spectrum. Also noted is an overall cortical increase in the alpha spectrum. The resting alert state of a neurotypical population is most prominently marked by a regulation of 7.5-11 Hz alpha throughout the cortex. The decreased in delta and theta suggests an up regulation of the prefrontal cortex and the anterior Cingulate Gyrus a site involved in substance use disorder (SUD).

Conclusion: A presence of dominant slow waves through the prefrontal cortex and the anterior Cingulate Gyrus is often associated with OCD, anxiety, impulsivity and cravings in addicted populations. It is conceivable that our initial finding of altered electrical activity of the brain using qEEG analysis suggests the NEAT-12 may induce a “normalization “of aberrant electrical activity of the cortical region of the brain known to occur during protracted abstinence of alcoholics. It may have utility as a putative anti-craving CES device and therefore warrants intensive investigation.

Introduction

The Cranial Electrical Stimulation (CES) technique appeared at the beginning of the 1960s and is aimed to act at the level of the central nervous system [1]. The current, composed of high frequency pulses interrupted with a repetitive low frequency, was delivered through three electrodes (a negative electrode placed between the eyebrows while two positive electrodes are located in the retro-mastoid region). We have recently introduced a new CES Device, the NEAT-12, in which shortcomings encountered with previous electrical stimulation techniques are avoided due to changes in the characteristics of the delivered current. The main property of CES is to potentiate some drug effects, especially opiates and neuroleptics, during anesthetic clinical procedures [2]. This potentiation effect permits a drastic reduction of pharmacological anesthetic agent and results in reduced postoperative complications. Despite numerous clinical and animal studies performed with this technique for several decades, CES mechanisms are not completely elucidated. Animal studies demonstrated that stimulationwith CES releases 5-hydroxy-indol-acetic acid and enkephalins [2]. These results obtained without any undesirable outcome are encouraging signs. Continued investigation of this electrotherapeutic technique is warranted.

Brief History

CES received U.S. Food and Drug Administration (FDA) approval for the treatment of insomnia, depression, and anxiety in 1979 [3]. CES is the United States FDA term for the transcranial application of small amounts of electricity, usually less than 300-600 mA with a frequency of 100 Hz or lower. CES was imported into the United States from Europe and was originally introduced as electro sleep, possibly because it increases delta waves. CES and electronic medicine did not receive a particularly warm reception in American medicine until clinicians began to utilize the transcutaneous electrical nerve stimulation (TENS) devices for pain. Electrotherapies have been used in psychiatry in the form of electroconvulsive therapy (ECT), which is still utilized in organic brain diseases such as Parkinson’s and organic-based depressions [4].

Scrutiny of Table 1 indicates that abundant research has established that an electroencephalogram (EEG) recorded from a drug abuser has a predictable distribution of electrical power (measured in micro-volts squared), just as does the electrocardiogram (EKG). The predictable electrical signals recorded by the EEG, distinctive for each brain region, are regulated by the homeostasis of a complex neuroanatomical brain system that utilizes all known neurotransmitters. Just as the EKG can be used to assess heart dysfunctions, the EEG can assess a wide variety of brain dysfunctions related to developmental, neurological and psychiatric disorders, whether caused by structural or functional abnormalities.

Table 1: QEEG, EEG changes in Substance Abuse.

Electrophysiological imbalances secondary to drug abuse have been well characterized (Table 1). These EEG abnormalities are similar in characteristic to the electrophysiological imbalances of various psychiatric diseases such as generalized anxiety, ADHD, depression, OCD and other impulsive disorders.

Abnormal behaviors involving dopaminergic gene polymorphisms often reflect an insufficiency of usual feelings of satisfaction, or Reward Deficiency Syndrome (RDS). RDS results from a dysfunction in the “brain reward cascade,” a complex interaction among neurotransmitters (primarily dopaminergic and opioidergic). Individuals with a family history of alcoholism or other addictions may be born with a deficiency in the ability to produce or use these neurotransmitters.

A number of earlier studies have examined the effect of CES on pain, headaches, fibromyalgia, smoking cessation, closed head injuries, and opiate withdrawal [22-24]. There have been a number of studies including some randomized double-blind, controlled experiments [25-31] on generalized anxiety and related symptoms using CES.

Substance use Disorder and CES

The use of CES as a potential modality for drug abuse was reviewed many years ago by Blum’s laboratory [32]. At that time we showed that in high risk drug abusers the P300 amplitude increased significantly (n=14, P<0.03) when the pre and post qEEG’s were compared. The CES device at a frequency of 100 pulses/sec.1.0 mA, 20% duty cycle, in a square wave form, was worn on the forehead and wrist for 40 minutes. Moreover, fifteen drug abusing individuals were evaluated in an eyes closed and eyes open computerized power spectral analysis for delta, theta, alpha, beta activity before and after 40 minutes of CES. Significant electrophysiological changes occurred in all of the subjects with abnormal baselines. When the pre and post-CES brain electrical activity mapping were compared, significant increases in delta, alpha and beta activity occurred, with a significant decrease in theta activity. We suggested that CES is a therapy that may beneficially alter the abnormal electrophysiology associated with drug abuse and it may normalize patterns of electrotherapy. Others have also studied the effects of CES and drug abuse [33-36]. Specifically, in a double blind placebo controlled investigation [35] it was shown that CES, comprising of the combination of a constant current with a pulse current of square impulses of 70-80 Hz, is an effective method to correct affective disturbances (anxiety, depression) in alcoholic patients. REF Krupitsky et al. [35] in Russia found that the medical effects of CES are accompanied by changes in the metabolism of GABA and monoamines, but not of beta-endorphin. These changes were accompanied by a decrease in the latency of alpha-rhythm appearance eyes closed qEEG.

While there have been a number of studies some of which are negative on the use of CES for the treatment of anxiety, insomnia and depression less is known about the use of CES in substance use disorder [37-39]. In fact there have been no studies related to Substance Use Disorder (SUD) in humans that we can find by doing a PubMed search (7-21-10) after 2000.

The objective of this study was to preliminarily explore whether a newly developed CES device as an effective therapy for patients with DSM-IV diagnosed SUD. This novel waveform is characterized by pulse width and current that is constant reacting independently on the resistant load. Our primary hypothesis was that Neuro-Electro- Adaptive Therapy 12™ [NEAT-12] would reverse dysynchronization of the orbital-prefrontal cortical electro-activity classically observed in protracted abstinence alcoholics. This device utilizes TENS current characteristics yielding CES effects. This is the first report describing not only the device but its putative benefits especially at the Cingulate Gyrus of the brain.

Method

Subject

The male was 42 years old with a two month period of sobriety. The subject was recruited from G & G Holistic Addition Center alumni group. He was diagnosed using DSM –IV criteria for SUD with emphasis on alcoholism. He was currently employed but complained about anxiety and a continuation of craving, “white knuckle” sobriety.

Study design

The study was approved by the PATH Foundation NY Institutional Review Board as part of an approved research project related to genetic testing and novel approaches to SUD treatment (RB NIH registration is # (IRB00002334). The patient signed a consent statement prior to the experiment. The patient was not taking any psychoactive medication at the time of the evaluation. He was drug free as assessed by urine testing. A qEEG analysis obtained one-day prior to NEAT-12 treatments was considered as the pretest. At the exact same time only one day later the patient utilized the NEAT 12 for a one-hour period. Immediately after this treatment the subject was re-evaluated by qEEG analysis.

The NEAT 12 has twelve independent programs associated to patient’s condition whether it is acute, sub-acute or chronic. The program used in this case study was for post chronic conditions. The current characteristics were 25 uA, at a frequency of 0.44 Hz, polarity change 2.25 seconds every 17 pulses with a modulated pulse. The electric parameters for the NEAT-12 device are shown in Table 1 and Figure 1.

The memory of the NEAT-12 device stores data for 12 different therapeutic waveforms and pulse sequences, each of which is described in Table 2.

In a current search of the existing devices approved for market by the FDA for Cranial Electrical Stimulation no device was found to have any similar waveform characteristics. Many claimed to have waveform harmonics which are trade secrets but from our research the duration, polarity and modulation of our waveform has very little resemblance of any other device on the market today.

qEEG procedure

Nineteen electrodes using an electro-cap consistent with the International 10/20 systems were placed. Routine EEG was recorded on a Cadwell Easy II using a linked ear montage and with electrodes digitally referenced to the Cz electrode allowing for retrospective montage analysis of all data. Using data gathered under technical conditions as listed above, 59.99 seconds of EEG were selected and subjected to quantitative analysis of absolute power, relative power, power asymmetry and coherence. These measurements are logarithmically transformed and referenced to age-adjusted population norms.

Figure 1: Description of NEAT Device and treatment protocol

Table 2: NEAT-12 programs.

Figure 2:QEEG analysis comparing pre-to post NEAT-12 in alcoholic patient.

Results

Frequency band magnitude (uV) topographies of the EC condition are presented below (Figure 2).

The absolute power changes represented in the above images shows a decrease of more than 2 SD as noted in the delta wave spectrum. Also noted is an overall cortical increase in the alpha spectrum. The resting alert state of a neuro typical population is most prominently marked by a regulation of 7.5-11 Hz alpha throughout the cortex. The decrease in delta and theta suggests an up regulation of the idling frequencies of the prefrontal cortex and the anterior Cingulate Gyrus. A presence of dominant slow waves through the prefrontal cortex and the anterior Cingulate Gyrus is often associated with OCD, Anxiety, and impulsivity.

To validate these findings a percentage change in microvolts squared was performed as presented by the below data (Figure 3). The percentage of relative power change is congruent with the previous findings noting a 25% decrease in prefrontal delta and an increase in cortical potential marked by the prefrontal increase in activity throughout the theta and alpha spectrum. The overall alpha increase of 15-25% suggests an up regulation in post synaptic potentials noting that the brain has a more power to self-regulate.

Figure 3:Validation experiment percentage change in microvoltâÂ?Â?s squared Frequency band normalized power (% uV2) topographies for the EC conditions are presented below.

Discussion

In comparison of pre to post CES treatment the aforementioned absolute power ranges in these findings support the use of the CES technology in ameliorating the electrophysiological correlates of obsessive compulsion, anxiety, impulsivity, and cravings in addicted individuals [3-4,22-45].

The exact mechanism of NEAT-12 is unclear. However several preliminary studies have shown that CES alters various neurotransmitters or hormone levels in the brain [43]. One study demonstrated increased catecholamine levels in men and women and increased thyroxin production in men following log-term therapy with CES [36]. Others reported that platelet monoamine oxidase –B (MAO-B) activity and plasma concentration of Gamma –amino butyric acid (GABA) increased following CES, in conjunction with clinical improvement in anxiety and depression [31]. Shealy [44] has repeatedly shown that in both normal volunteers and in volunteers with treatment resistant depression, that CES was associated with significant elevations in cerebrospinal fluid and plasma serotonin respectively. CES has also been found to alter EEG readings in macaque monkeys during and after treatment. Alpha EEG waves were slowed following CES, which was associated with a reduction in adverse reactions to stressful stimuli [36,45]. In addition the observed attenuation of the high beta band with 100HZ CES treatment has clinical importance because this high beta band is associated with arousal, problem solving and stress [45]. Thus a slowing of alpha EEG waves coupled with a reduction of high beta bands together impact ones reaction to a stressful stimuli.

In our (ERB’s) clinical experience, long –term, daily 30-60 minutes CES treatment helped drug abusers to reduce, eliminate, and/or substitute the action of anti-depressants and benzodiazepines.

Based on the qEEG results, overall alpha increase of 15-25%, it is reasonable to expect that the use of this CES device by our abstinent alcoholic patient resulted in decreased stress. However, this pilot study must be confirmed by a large double-blind-sham controlled study in a well-characterized SUD population before anything definitive can be established.

To maintain homeostasis of the complex neuroanatomical brain system that utilizes neurotransmitters, poly-drug abusers who are known to be deficient in the neurotransmitters, may require continuous supplemental Neuroadaptogen Amino-Acid Therapy (NAAT) for neurotransmitter augmentation [46].

Our group Blum et al. [46]. have now completed a number of new studies using qEEG and functional magnetic resonance imaging (fMRI) showing that NAAT (specifically, Synaptose Complex Variant [KB220-Z]™) normalizes the electro-activity of the pre-frontal and cingulated gyrus region of the brain similar to the NEAT 12 devise in protracted poly-drug abusers with Reward Deficiency Syndrome (RDS) [47,48]. Use of this natural non-addicting, safe putative D2 agonist may find its place in recovery from (RDS) including addiction to psychoactive chemicals. We also cautiously suggest that longterm activation of dopaminergic receptors (i.e., DRD2 receptors) with NAAT will result in the proliferation of D2 receptors leading to enhanced “dopamine sensitivity” and an increased sense of happiness [49]. This is supported by numerous clinical trials on KB220 and awaits both fMRI and PET scanning to determine chronic effects of KB220-Z on numbers of D2 receptors and direct interaction at NAc.

Positive outcomes demonstrated by qEEG imaging in a randomized Triple-blind placebo controlled study involving oral KB220-Z, showed an increase of Alpha and low Beta activity [48]. Moreover, preliminary unpublished evidence derived from our fMRI studies in China indicate that an acute dose of KB220-Z compared to placebo in a double blinded study at rest activated the dopaminergic NAc as well as smoothing out abnormalities observed in the Putamen of heroin addicts. Additional addiction behavioral research involving cue induced reward site activation using fMRI is ongoing in China. These results will provide important information that could ultimately lead to significant improvement of recovery for victims of RDS having dopamine deficiency.

It is noteworthy, that alcohol may produce addiction by normalizing abnormal baseline states such as irritability, hyperexcitability, dysphoria, impulsiveness, or anxiety [50]. The results of animal studies have revealed that alcohol can induce sensitivity of neuronal membranes, chemically altered proteins, and adaptations to ion channels and factors related to the binding and release of neurotransmitters and neuromodulators including serotonin, pro-opiomelanocortins, enkephalins, gamma aminobutyric acid, glutamate receptors, and dopamine, norepinephrine and acetylcholine [51]. These effects could manifest via dopamine abducts with acetaldehyde leading to opioid – like actions and potential opioid receptor binding [52-54]. It is quite possible that modulation by NEAT-12 could offset impulsiveness, for example, as only one important target requiring intensive investigation.

While NEAT -12 are not strictly a CES device but a hybrid whereby we utilized current characteristics of TENS, we are encouraged that in larger cohort double-blinded studies it will produce similar CES effects as observed in this case study. A limitation to the use of this device is that its effects are only transient and must be coupled with natural Dopamine D2 agonistic therapy such as NAAT or newly developed variants for further longer term D2 activation in both the posterior VTA and Cingulate gyrus.

Conclusion

The results of this pilot study are encouraging and we are proposing that NEAT-12 could provide adjunctive benefits to the addicted individual by reducing break-through aberrant cravings especially in conjunction with NAAT.

We propose following validation in large controlled studies, the systematic coupling of, RDS Inventory scale, genetic testing, personalized nutrigenomic (NAAT) solutions and NEAT 12, and Comprehensive Analysis of Reported Drugs™ (a medical monitoring system by Dominion Diagnostics) and miRNA monitoring (gene expression) as a potential RDS solution system if executed properly could revolutionize the RDS recovery field and ultimately provide an important contribution to the resolution of the ongoing difficulty we face in treating addiction and relapse [55,56].

Acknowledgements

The authors appreciate the edits of Margaret A. Madigan. In Part the writing of this manuscript was supported by a grant awarded to MOB from the National Institutes of Health, NIAAA grant (RO1-AA07112) and KO5-AA00219, and support from the medical Research Service of the US Department of Veterans Affairs. The writing of this manuscript was in part supported by a grant awarded to Kenneth Blum and Eric R. Braverman of PATH Foundation NY, from Life Extension Foundation, Ft. Lauderdale, Florida. We appreciate the support of the PATH NY staff especially Courtney Truesdell, Mona Li, Kristina Dushaj and Florian Kreuk. The authors are also appreciative of the expert experimental research of the staff of the National Institute for Holistic Addiction Studies. We are thankful of the expert QEEG technology developed by C. Allen.

Conflict of Interest

Roger L Waite, and Kenneth Blum own stock in Bio Clarity LLC., worldwide distributors of the NEAT 12 device based on US and Foreign Patents pending.

References

1. Gilula MF (2007)
2. Zaghi S, Acar M, Hultgren B, Boggio PS, Fregni F (2010)
4. Post RM, Trimble MR, Pippenger CE (1989) Clinical use of anti-convulsive in psychiatric disorders. New York, Demos Publications.
5. Saletu B, Anderer P, Saletu-Zyhlarz GM, Arnold O, Pascual-Marqui RD (2002)
6. Finn PR, Justus A (1999)
7. Kaplan RF, Glueck BC, Hesselbrock MN, Reed HB Jr (1985)
8. Michael A, Mirza KA, Mukundan CR, Channabasavanna SM (1993)
9. Winterer G, Enoch MA, White KV, Saylan M, Coppola R, et al. (2003)
10. de Bruin EA, Stam CJ, Bijl S, Verbaten MN, Kenemans JL (2006)
11. Struve FA, Straumanis JJ, Patrick G, Price L (1989)
12. Struve FA, Manno BR, Kemp P, Patrick G, Manno JE (2003)
13. Polunina AG, Davydov DM (2004)
14. Franken IH, Stam CJ, Hendriks VM, van den Brink W (2004)
15. Bauer LO (2001)
16. Prichep LS, Alper KR, Sverdlov L, Kowalik SC, John ER, et al. (2002)
17. Alper KR (1999)
18. Roemer RA, Cornwell A, Dewart D, Jackson P, Ercegovac DV (1995)
19. Reid MS, Flammino F, Howard B, Nilsen D, Prichep LS (2006)
20. Venneman S, Leuchter A, Bartzokis G, Beckson M, Simon SL, et al.(2006)
21. Ceballos NA, Bauer LO, Houston RJ (2009)
22. Kirsch DL, Smith RB (2000)
23. Solomon S, Elkind A, Freitag F, Gallagher RM, Moore K, et al. (1989)
24. Smith RB, Tiberi A, Marshall J (1994)
25. Long RC (1966)
26. Buckman C, Pinsley I, Fenichel M (1957)
27. Bystritsky A, Kerwin L, Feusner J (2008)
28. Flemenbaum A (1974)
29. Moore JA, Mellor CS, Standage KF, Strong H (1975)
30. Philip P, Demotes-Mainard J, Bourgeois M, Vincent JD (1991)
31. Klawansky S, Yeung A, Berkey C, Shah N, Phan H, et al. (1995)
32. Braverman ER, Smith R, Smayda R, Blum K (1990) Modification of P330 amplitude and other electrophysiological parameters of drug abuse by cranial electrical stimulation. Cur Therap Res 48: 586-596.
33. Schmitt R, Capo T, Frazier H, Boren D (1984)
34. Schmitt R, Capo T, Boyd E (1986)
35. Krupitsky EM, Burakov AM, Karandashova GF, Katsnelson JaS, Lebedev VP, et al. (1991)
36. Jarzembski WB (1985)
37. Demotes-Mainard J, Philip P, Jalfre M, Vincent JD (1990)
38. Pickworth WB, Fant RV, Butschky MF, Goffman AL, Henningfield JE (1997)
39. Auriacombe M, Tignol J, Le Moal M, Stinus L (1990)
40. Stinus L, Auriacombe M, Tignol J, Limoge A, Le Moal M (1990)
41. Alling FA, Johnson BD, Elmoghazy E (1990)
42. Braverman ER, Blum K, Smayda RJ (1990) A commentary on brain mapping in 60 substance abusers: Can the potential for drug abuse be predicted and prevented by treatment? Curr Ther Res 48: 569.
43. Ferdjallah M, Bostick FX Jr, Barr RE (1996)
44. Shealy CN (2003)
45. Schroeder MJ, Barr RE (2001)
46. Blum K, Oscar-Berman M, Stuller E, Miller D, Giordano J, et al. (2012)
47. Miller D, Manka M, Miller M, Stokes S, Allen C, et al. (2010)
48. Blum K, Chen TJH, Morse S, Giordano J, Chen ALC, et al. (2010) Overcoming qEEG abnormalities and reward gene deficits during protracted abstinence in psychostimulant abusers utilizing putative dopamine D2 agonist therapy. Part 2. Postgraduate Medicine 122: 214-226.
49. Blum K, Chen AL, Chen TJ, Braverman ER, Reinking J, et al. (2008)
50. Archer T, Oscar-Berman M, Blum K, Gold M (2012)
51. Shan HQ, Hammarback JA, Godwin DW (2013)
52. Blum K, Hamilton MG, Hirst M, Wallace JE (1978)
53. Blum K, Wallace JE, Ryback RS, Geller I (1972)
54. Blum K, Sheridan PJ, Wood RC, Braverman ER, Chen TJ, et al. (1995)
55. Blum K, Chen TJ, Downs BW, Bowirrat A, Waite RL, et al.(2009)
56. Dahlgren A, Wargelius HL, Berglund KJ, Fahlke C, Blennow K, et al. (2011)